Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
BACKGROUND
The effects of an oral contraceptive pill containing cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome (PCOS) was studied.


METHODS
Seventy-two women with PCOS were treated for 36 consecutive cycles with an oral contraceptive containing 0.035 mg of ethinylestradiol and 2 mg of cyproterone acetate. Hormonal, lipid and glucose profiles were studied before and after 12 and 36 cycles of treatment. Lipid, lipo-and apolipoprotein values were compared to a healthy control group. Statistical analysis was by one way analysis of variance and Bonferroni's t tests.


RESULTS
The treatment suppressed gonadotropin and androgen values and increased the levels of sex hormone binding globulin. After 12 and 36 cycles a significant increase in triglycerides, high density lipoprotein (HDL) cholesterol system, and apoprotein B levels was seen. Low density lipoprotein (LDL) cholesterol and LDL cholesterol/HDL cholesterol ratio were reduced. Insulin and glucose plasma concentrations did not change. During treatment triglycerides, total cholesterol and apoprotein B values were higher than in the control group. There were no differences in plasma levels of LDL-C and HDL-C in PCOS and in the control group.


CONCLUSIONS
Lipid and lipoprotein changes observed after treatment could be due to the estrogen dominance of the treatment. The plasma concentration of triglycerides and total cholesterol during treatment does not change appreciably and the LDL-C/HDL-C ratio improved.
Falsetti
L
L
Department of Gynecological Endocrinology, University of Brescia, Italy.
Pasinetti
E
E
D000328:Adult; D001059:Apoproteins / Q000032:analysis; D002784:Cholesterol / Q000378:metabolism; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000494:pharmacology*; D017373:Cyproterone Acetate / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000139:chemically induced; D050356:Lipid Metabolism; D008074:Lipoproteins / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D011247:Pregnancy; D013739:Testosterone / Q000032:analysis; D014280:Triglycerides / Q000378:metabolism
D001059:Apoproteins; D003278:Contraceptives, Oral, Hormonal; D008074:Lipoproteins; D014280:Triglycerides; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D002784:Cholesterol